when were glp-1 agonists approved for weight loss Glucagon-Like Peptide (GLP)-1 Drugs Market Report 2026 Featuring Major Players Novo Nordisk A/S, Eli Lilly and Company, and Pfizer GLP-1s for Weight Loss: What

Cardiovascular and renal outcome trials reporting outcomes on GLP-1RA, SGLT-2 inhibitors and DPP-4 inhibitors in patients with or without type 2 diabetes mellitus were included

If you look closely at the bottom panels of the 2 graphs above for loss of body weight, the participants in the new trial had 40% less weight loss than in the previous trial of obese, non-diabetic participants

Chippewa Valley Technical College

Demand for such drugs is likely to continue to be strong in the future due to rising rates of obesity and interlinked chronic diseases

As we mentioned before, GLP-1R agonism is able to ameliorate neuroinflammation and behavioral deficits induced by hepatectomy or neuropathic pain (63, 64)

GLP-1 RAs impact cardiac myocytes in conditions such as myocardial infarction, heart failure preserved ejection fraction (HFpEF), and cardiomyopathy